Sarepta Therapeutics Sees Setback in Eteplirsen Drug Application

Sarepta Therapeutics Inc. said the U.S. Food and Drug Administration is requiring additional data for the new drug application for its Duchenne muscular dystrophy treatment eteplirsen.



from WSJ.com: US Business http://ift.tt/1wv5OB4

via IFTTT